This research focused on a specific group of patients with chronic myeloid leukemia in the chronic phase. These participants had either stopped responding to earlier tyrosine-kinase inhibitor therapies or possessed the T315I mutation. The team investigated whether taking ponatinib once daily at starting doses of 45 mg, 30 mg, or 15 mg would help achieve a molecular response by the 12-month mark.
The study tracked participants for an average of nearly five years. While the specific percentage of people reaching the primary molecular response goal was not reported in the available data, the trial design aimed to evaluate efficacy across these different dosage levels. Safety information regarding adverse events, serious reactions, or drug discontinuations was also not reported in the provided details.
Readers should understand that this is a Phase 2 study, which is an intermediate step before large-scale testing. The lack of reported safety data and specific outcome numbers means the full picture of risks and benefits is not yet clear. Until larger trials confirm these findings, this evidence should not be used to change current treatment plans without consulting a healthcare professional.
